Abstract
Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian Consortium for Locally Advanced Breast Cancer (LABC) was established with the goal to convene a strong multidisciplinary team of breast oncology clinicians and scientists who are dedicated to the advancement of LABC research and treatment, with a vision to drive progress through increased collaboration across disciplines and throughout Canada. The most recent meeting in May 2017 highlighted the latest evidence and literature about the optimal use of neoadjuvant systemic therapy in breast cancer. There is a need for increased clinical and scientific collaboration and the development of guidelines for the use of emerging treatment strategies. The interactive meeting sessions fostered unique opportunities for academic debate and nurtured collaboration between the attendees.
Highlights
Therapy for early breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy
Chemotherapy has been administered to bca patients after surgery, followed by radiation and hormonal therapy
The nsabp B-51/Radiation Therapy Oncology Group 1304 trial and the Alliance A11202 trial are currently evaluating the role of regional nodal radiation after nac in slnb-negative and slnb-positive patients treated with bcs and mastectomy
Summary
Therapy for early breast cancer (bca) involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. For postmenopausal women with a clinical stage ii/ iii hormone receptor–positive bca, neoadjuvant endocrine therapy (netx) is an underutilized and low-toxicity potential alternative to chemotherapy for increasing breast conservation rates[10]. That approach is an area of evolving research: two new trials have opened in Canada to investigate the role of slnb and regional lymph node radiation in patients with upfront node-positive disease who are rendered clinically node-negative after nac[15,16,20,21].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
